CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Want to see HK:1228 full AI Analyst Report?
1228 Stock Chart & Stats
HK$2.52
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.52
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$0.13 - HK$3.50
Previous CloseN/A
Volume661.00K
Average Volume (3M)5.03M
Market Cap
HK$1.30B
Enterprise ValueHK$756.95M
Total Cash (Recent Filing)HK$1.96M
Total Debt (Recent Filing)HK$34.97M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,443,360
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)-3.05
Price to Sales (P/S)21.42
P/FCF Ratio-27.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
Bulls Say, Bears Say
Bulls Say
Rare-disease / Specialty FocusA sustained focus on rare diseases and underserved conditions creates a specialized R&D and commercial strategy with clearer target patient populations and regulatory pathways. This niche focus supports durable partner interest and long-term product differentiation versus broad-market competitors.
Diversified Monetization ModelMultiple revenue streams — product sales, licensing/milestones/royalties and service income — provide structural optionality. Licensing partnerships and milestone-driven cash inflows are durable sources of non-dilutive funding that can de-risk development timelines and smooth revenue volatility over time.
Relatively Strong Gross MarginsSustained gross margins in the low-60% to low-70% range indicate product-level profitability potential. As commercial scale improves, these margins provide leverage to absorb fixed R&D and SG&A, improving prospects for eventual operating margin recovery and sustainable cash generation.
Bears Say
Negative Shareholders' EquityPersistent negative shareholders’ equity materially weakens financial flexibility, complicates access to unsecured capital and can raise creditor and investor concern. Over months, this structural capital weakness increases reliance on dilutive financing or restrictive covenanted debt.
Ongoing Cash BurnNegative operating and free cash flow each year signals the business cannot self-fund operations. Although burn improved in 2025, sustained negative cash generation elevates refinancing and dilution risk and limits the company’s ability to invest organically without external capital.
Sharp Revenue Contraction / Volatile Top-lineA steep revenue decline and high volatility undermine scale economics and make fixed-cost absorption harder. Combined with persistently negative EBIT margins, weak and inconsistent top-line trends reduce the visibility of durable commercialization success and heighten execution risk.
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.13 and its highest was HK$3.50 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.30B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Aug 28, 2026 which is in 112 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.095 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.095.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 595,443,360 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of -HK$0.095 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.382%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
696.29%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
48.19%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---